{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"23"}],"units":"Participants"}],"description":"The RP2D of lenvatinib in combination with everolimus was determined by Dose Escalation Committee (DEC) based on safety (including DLTs), pharmacokinetic and clinical data. DLT was graded according to CTCAE v4.03.","groups":[{"description":"Participants with recurrent or refractory solid tumors received lenvatinib 8 or 11 mg/m\\^2, capsules, orally, once daily in combination with everolimus 3 mg/m\\^2, tablets, orally, once daily in cycle 1 (each cycle was 28 days) until the occurrence of PD, clinical benefit, development of unacceptable toxicity leading to withdrawal from the study, study discontinuation or for a maximum of 18 cycles (each cycle was 28 days) whichever occurred first.","id":"OG000","title":"Phase 1: Lenvatinib + Everolimus (All Participants)"}],"paramType":"NUMBER","populationDescription":"SAS included all participants who received at least one dose of study drug (Lenvatinib or Everolimus).","reportingStatus":"POSTED","timeFrame":"Cycle 1 (Each cycle was of 28 days)","title":"Phase 1: Recommended Phase 2 Dose (RP2D) of Lenvatinib in Combination With Everolimus","type":"PRIMARY","unitOfMeasure":"mg/m^2"}